Solid Tumor Immunotherapy
BioNTech Cell & Gene Therapies GmbH focuses on solid tumors with an emphasis on cell therapy and immune-based cancer treatment, including CAR-T approaches directed at tumor-associated targets.
- CLDN6-targeted cancer therapy
- Adoptive T-cell treatment
- Organ tumor oncology
The research activity also includes combinations with RNA-based vaccine strategies in patients with solid malignant disease.
Cell and Gene Therapy Development
The sponsor is engaged in cell and gene therapy research centered on engineered immune cells, with attention to therapeutic platforms designed for oncology applications.
- Engineered T-cell products
- Autologous cell therapy
- Therapeutic gene-based constructs
Its clinical work reflects interest in advanced biological treatments for cancer targets that are difficult to address with conventional modalities.
RNA-Based Cancer Vaccines
BioNTech Cell & Gene Therapies GmbH is also involved in RNA-LPX vaccine research, particularly as an adjunct to cellular immunotherapy in tumor immunology.
- Messenger RNA-driven vaccine concepts
- Liposomal vaccine formulations
- Combination immunotherapy
This area of interest links vaccine-based immune activation with targeted cancer cell recognition.
Translational Oncology
The clinical research portfolio is concentrated on translating tumor antigen-directed therapies into patient care, with a focus on early oncology development and treatment options for advanced cancers.
- Tumor-associated antigen targeting
- Precision oncology
- Advanced solid malignancies
Current activity spans multiple countries and collaborating sites in support of clinical evaluation in oncology.
